Latigo Biotherapeutics, Inc. has made a significant update regarding its beneficial ownership in a recent filing. The company's latest Schedule 13G/A, filed on November 6, 2026, reveals that AI Biotechnology LLC and its affiliates now hold a combined 4.8% stake in Latigo, which may have implications for the company's strategic direction and partnerships.

This update is crucial for Latigo as it reflects the growing interest from significant investors in the pharmaceutical preparations sector. The filing indicates that AI Biotechnology LLC, along with Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik, collectively own 3,193,565 shares of Latigo's common stock. This stake signifies a noteworthy level of influence that these entities may exert on Latigo's future decisions and operations.

Background

Latigo Biotherapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company trades under the ticker LTGO on the Nasdaq exchange. Latigo is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company. The recent Schedule 13G/A filing is part of a series of disclosures made by Latigo, including a 10-Q and an 8-K, which were also filed on November 5, 2026.

What the Filing Says

The Schedule 13G/A filing states, "The percentage reported herein is calculated based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 5, 2026." This indicates a clear calculation of ownership and reflects the transparency required in such disclosures.

Impact

This update may significantly affect the stakeholders of Latigo Biotherapeutics, including its management, shareholders, and potential partners. The involvement of AI Biotechnology LLC and its affiliates suggests that Latigo could be positioned for strategic initiatives or collaborations that may enhance its market presence and operational capabilities.

What's Next

The filing does not specify what happens next for Latigo Biotherapeutics following this update. However, the increased ownership stake by AI Biotechnology LLC could lead to further developments in strategic partnerships or operational changes in the near future.